EVH:NYE-Evolent Health Inc Class A (USD)

EQUITY | Health Information Services | New York Stock Exchange

Last Closing

USD 20

Change

+0.26 (+1.32)%

Market Cap

USD 1.38B

Volume

1.75M

Analyst Target

USD 11.67
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Evolent Health Inc is engaged in healthcare delivery and payment. It markets and sells its services to providers throughout the United States.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-05 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
SOLV Solventum Corp.

+0.48 (+0.71%)

USD 10.78B
DOCS Doximity Inc

+0.46 (+1.06%)

USD 7.70B
WEAV Weave Communications Inc

+0.47 (+3.75%)

USD 0.89B
AMWL American Well Corp

+0.29 (+3.20%)

USD 0.14B
MPLN MultiPlan Corporation

+1.02 (+12.78%)

USD 0.12B
OWLT Owlet Inc

-0.07 (-1.53%)

USD 0.07B
STRM Streamline Health Solutions In..

+2.37 (+1,185.64%)

USD 0.01B
LFMDP LifeMD Inc Preferred Series A

-0.25 (-1.12%)

N/A
TDOC Teladoc Inc

+0.36 (+4.15%)

N/A
FOXO FOXO Technologies Inc.

N/A

N/A

ETFs Containing EVH

EDOC:AU BetaShares Digital Health.. 4.65 % 0.00 %

-0.10 (-1.08%)

N/A
DDOC:F Global X Telemedicine & D.. 4.15 % 0.00 %

-0.11 (-1.08%)

USD 4.62M
ACTV LeaderShares® Activist L.. 0.00 % 0.00 %

+0.60 (+-1.08%)

N/A
DDOC:XETRA Global X Telemedicine & D.. 0.00 % 0.00 %

+0.04 (+-1.08%)

USD 5.39M

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -39.45% 36% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -39.45% 36% F 3% F
Trailing 12 Months  
Capital Gain -32.50% 45% F 8% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return -32.50% 45% F 7% C-
Trailing 5 Years  
Capital Gain 162.12% 100% F 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 162.12% 100% F 92% A
Average Annual (5 Year Horizon)  
Capital Gain 51.57% 100% F 95% A
Dividend Return 51.57% 100% F 95% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 70.97% 27% F 11% F
Risk Adjusted Return 72.66% 100% F 89% A-
Market Capitalization 1.38B 73% C 65% D

Key Financial Ratios

  Ratio vs. Industry/Classification (Health Information Services) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 643.99 17% 1%
Price/Book Ratio 3.21 55% 27%
Price / Cash Flow Ratio 15.38 36% 24%
Price/Free Cash Flow Ratio -156.69 100% 99%
Management Effectiveness  
Return on Equity -8.75% 75% 18%
Return on Invested Capital 1.24% 58% 28%
Return on Assets 0.62% 67% 27%
Debt to Equity Ratio 55.92% 83% 57%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.